Nov 17, 2011
US consumer advocacy group Consumers Union is arguing that Congress strengthen the Food and Drug Administration's ability to regulate medical devices in order to improve quality, safety and effectiveness.
The group has sent a letter to Congress contending that despite industry lobbying efforts casting medical device regulations as barriers to innovation, devices remain less regulated than pharmaceutical products in the US.
The Consumers Union letter also takes issue with the FDA's practice of clearing most devices through the 510(k) process without requiring clinical trials, as well as the agency's reliance on Substantial Equivalence as a key consideration during device reviews.
Recommendations for pre-market approval improvements the group's letter imparts to Congress include:
Consumers Union also argues for improvements to the FDA's post-market surveillance practices for devices:
These recommendations are not new, according to Consumers Union: along with other consumer advocacy organizations, the group argued for adoption of these steps five years ago.
Given the substantial resources and legislative connections industry lobbyists have at their disposal, however, Consumers Union will likely have to make the same argument in another five years.
The US Food and Drug Administration has extended its comment period to November 28, 2011 for guidance the agency issued
New draft guidance from the US Food and Drug Administration would reclassify some in vitro
A long-awaited report issued July 27 by the Institute of Medicine of the National Academies (IOM) has recommended that the US Food and Drug Administration (FDA) replace its current 510(k) program for Class II medical device reviews with a new process that does not rely on substantial equivalence for clearance decisions.